8-K current report · filed Aug 3, 2026

TG THERAPEUTICS, INC. (TGTX) 8-K Current Report: August 3, 2026

Item EX-99.1Item 2.02TGTX overview

Short answer

TG THERAPEUTICS, INC. (TGTX) filed an 8-K current report with the SEC on August 3, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Press release announces TG Therapeutics’ second-quarter and first-half 2026 operating results.

TG THERAPEUTICS, INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Press release announces TG Therapeutics’ second-quarter and first-half 2026 operating results
  • Results cover the three and six months ended June 30, 2026
  • Full financial details and management commentary are in Exhibit 99.1

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $240.3M, up from $141.1M; BRIUMVI U.S. sales $227.7M, up approximately 64% year over year
  • 2026 guidance raised to approximately $950M global revenue and $890–905M BRIUMVI U.S. revenue
  • Net income fell to $7.8M from $28.2M as R&D reached $95.3M and SG&A $82.1M
  • Cash, equivalents and investments $612.3M, supporting commercialization and pipeline investment
  • Positive ENHANCE results support single 600 mg initiation infusion; subcutaneous Phase 3 data expected year-end 2026 or early 2027

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other TG THERAPEUTICS, INC. 8-K filings

Get the next TGTX 8-K as it lands

Follow TGTX for push alerts, or ask the research agent what this filing means.